Copyright Reports & Markets. All rights reserved.

Global Biosimilar Monoclonal Antibodies Market Insights and Forecast to 2027

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Biosimilar Monoclonal Antibodies Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type
    • 1.4.2 Infliximab
    • 1.4.3 Rituximab
    • 1.2.4 Trastuzumab
    • 1.2.5 Adalimumab
    • 1.2.6 Other
  • 1.3 Market by Application
    • 1.3.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application
    • 1.3.2 Oncology
    • 1.3.3 Autoimmune Disease
    • 1.3.4 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global Biosimilar Monoclonal Antibodies Sales Estimates and Forecasts 2016-2027
  • 2.2 Global Biosimilar Monoclonal Antibodies Revenue Estimates and Forecasts 2016-2027
  • 2.3 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2016 VS 2021 VS 2027
  • 2.4 Global Top Biosimilar Monoclonal Antibodies Regions by Sales
    • 2.4.1 Global Top Biosimilar Monoclonal Antibodies Regions by Sales (2016-2021)
    • 2.4.2 Global Top Biosimilar Monoclonal Antibodies Regions by Sales (2022-2027)
  • 2.5 Global Top Biosimilar Monoclonal Antibodies Regions by Revenue
    • 2.5.1 Global Top Biosimilar Monoclonal Antibodies Regions by Revenue (2016-2021)
    • 2.5.2 Global Top Biosimilar Monoclonal Antibodies Regions by Revenue (2022-2027)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global Biosimilar Monoclonal Antibodies Sales by Manufacturers
    • 3.1.1 Global Top Biosimilar Monoclonal Antibodies Manufacturers by Sales (2016-2021)
    • 3.1.2 Global Top Biosimilar Monoclonal Antibodies Manufacturers Market Share by Sales (2016-2021)
    • 3.1.3 Global Top 10 and Top 5 Companies by Biosimilar Monoclonal Antibodies Sales in 2020
  • 3.2 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers
    • 3.2.1 Global Top Biosimilar Monoclonal Antibodies Manufacturers by Revenue (2016-2021)
    • 3.2.2 Global Top Biosimilar Monoclonal Antibodies Manufacturers Market Share by Revenue (2016-2021)
    • 3.2.3 Global Top 10 and Top 5 Companies by Biosimilar Monoclonal Antibodies Revenue in 2020
  • 3.3 Global Biosimilar Monoclonal Antibodies Sales Price by Manufacturers
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global Biosimilar Monoclonal Antibodies Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Biosimilar Monoclonal Antibodies Sales by Type
    • 4.1.1 Global Biosimilar Monoclonal Antibodies Historical Sales by Type (2016-2021)
    • 4.1.2 Global Biosimilar Monoclonal Antibodies Forecasted Sales by Type (2022-2027)
    • 4.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2027)
  • 4.2 Global Biosimilar Monoclonal Antibodies Revenue by Type
    • 4.2.1 Global Biosimilar Monoclonal Antibodies Historical Revenue by Type (2016-2021)
    • 4.2.2 Global Biosimilar Monoclonal Antibodies Forecasted Revenue by Type (2022-2027)
    • 4.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2016-2027)
  • 4.3 Global Biosimilar Monoclonal Antibodies Price by Type
    • 4.3.1 Global Biosimilar Monoclonal Antibodies Price by Type (2016-2021)
    • 4.3.2 Global Biosimilar Monoclonal Antibodies Price Forecast by Type (2022-2027)

5 Market Size by Application

  • 5.1 Global Biosimilar Monoclonal Antibodies Sales by Application
    • 5.1.1 Global Biosimilar Monoclonal Antibodies Historical Sales by Application (2016-2021)
    • 5.1.2 Global Biosimilar Monoclonal Antibodies Forecasted Sales by Application (2022-2027)
    • 5.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2027)
  • 5.2 Global Biosimilar Monoclonal Antibodies Revenue by Application
    • 5.2.1 Global Biosimilar Monoclonal Antibodies Historical Revenue by Application (2016-2021)
    • 5.2.2 Global Biosimilar Monoclonal Antibodies Forecasted Revenue by Application (2022-2027)
    • 5.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2016-2027)
  • 5.3 Global Biosimilar Monoclonal Antibodies Price by Application
    • 5.3.1 Global Biosimilar Monoclonal Antibodies Price by Application (2016-2021)
    • 5.3.2 Global Biosimilar Monoclonal Antibodies Price Forecast by Application (2022-2027)

6 North America

  • 6.1 North America Biosimilar Monoclonal Antibodies Market Size by Type
    • 6.1.1 North America Biosimilar Monoclonal Antibodies Sales by Type (2016-2027)
    • 6.1.2 North America Biosimilar Monoclonal Antibodies Revenue by Type (2016-2027)
  • 6.2 North America Biosimilar Monoclonal Antibodies Market Size by Application
    • 6.2.1 North America Biosimilar Monoclonal Antibodies Sales by Application (2016-2027)
    • 6.2.2 North America Biosimilar Monoclonal Antibodies Revenue by Application (2016-2027)
  • 6.3 North America Biosimilar Monoclonal Antibodies Market Size by Country
    • 6.3.1 North America Biosimilar Monoclonal Antibodies Sales by Country (2016-2027)
    • 6.3.2 North America Biosimilar Monoclonal Antibodies Revenue by Country (2016-2027)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe Biosimilar Monoclonal Antibodies Market Size by Type
    • 7.1.1 Europe Biosimilar Monoclonal Antibodies Sales by Type (2017-2027)
    • 7.1.2 Europe Biosimilar Monoclonal Antibodies Revenue by Type (2017-2027)
  • 7.2 Europe Biosimilar Monoclonal Antibodies Market Size by Application
    • 7.2.1 Europe Biosimilar Monoclonal Antibodies Sales by Application (2017-2027)
    • 7.2.2 Europe Biosimilar Monoclonal Antibodies Revenue by Application (2017-2027)
  • 7.3 Europe Biosimilar Monoclonal Antibodies Market Size by Country
    • 7.3.1 Europe Biosimilar Monoclonal Antibodies Sales by Country (2017-2027)
    • 7.3.2 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2017-2027)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Type
    • 8.1.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Type (2018-2027)
    • 8.1.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Type (2018-2027)
  • 8.2 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Application
    • 8.2.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Application (2018-2027)
    • 8.2.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Application (2018-2027)
  • 8.3 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Region
    • 8.3.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2018-2027)
    • 8.3.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2018-2027)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America Biosimilar Monoclonal Antibodies Market Size by Type
    • 9.1.1 Latin America Biosimilar Monoclonal Antibodies Sales by Type (2019-2027)
    • 9.1.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Type (2019-2027)
  • 9.2 Latin America Biosimilar Monoclonal Antibodies Market Size by Application
    • 9.2.1 Latin America Biosimilar Monoclonal Antibodies Sales by Application (2019-2027)
    • 9.2.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Application (2019-2027)
  • 9.3 Latin America Biosimilar Monoclonal Antibodies Market Size by Country
    • 9.3.1 Latin America Biosimilar Monoclonal Antibodies Sales by Country (2019-2027)
    • 9.3.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2027)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

6 Middle East and Africa

  • 6.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Type
    • 6.1.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Type (2016-2027)
    • 6.1.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Type (2016-2027)
  • 6.2 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Application
    • 6.2.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Application (2016-2027)
    • 6.2.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Application (2016-2027)
  • 6.3 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country
    • 6.3.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2016-2027)
    • 6.3.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2016-2027)
    • 6.3.3 Turkey
    • 6.3.4 Saudi Arabia
    • 6.3.5 U.A.E

11 Company Profiles

  • 11.1 Celltrion
    • 11.1.1 Celltrion Corporation Information
    • 11.1.2 Celltrion Overview
    • 11.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Description
    • 11.1.5 Celltrion Related Developments
  • 11.2 Pfizer (Hospira)
    • 11.2.1 Pfizer (Hospira) Corporation Information
    • 11.2.2 Pfizer (Hospira) Overview
    • 11.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Description
    • 11.2.5 Pfizer (Hospira) Related Developments
  • 11.3 3SBIO
    • 11.3.1 3SBIO Corporation Information
    • 11.3.2 3SBIO Overview
    • 11.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Description
    • 11.3.5 3SBIO Related Developments
  • 11.4 Novartis (Sandoz)
    • 11.4.1 Novartis (Sandoz) Corporation Information
    • 11.4.2 Novartis (Sandoz) Overview
    • 11.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Description
    • 11.4.5 Novartis (Sandoz) Related Developments
  • 11.5 Dr Reddy’s
    • 11.5.1 Dr Reddy’s Corporation Information
    • 11.5.2 Dr Reddy’s Overview
    • 11.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Description
    • 11.5.5 Dr Reddy’s Related Developments
  • 11.6 Celgen Biopharma
    • 11.6.1 Celgen Biopharma Corporation Information
    • 11.6.2 Celgen Biopharma Overview
    • 11.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Description
    • 11.6.5 Celgen Biopharma Related Developments
  • 11.7 Cadila Healthcare
    • 11.7.1 Cadila Healthcare Corporation Information
    • 11.7.2 Cadila Healthcare Overview
    • 11.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Description
    • 11.7.5 Cadila Healthcare Related Developments
  • 11.8 Hisun Pharma
    • 11.8.1 Hisun Pharma Corporation Information
    • 11.8.2 Hisun Pharma Overview
    • 11.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Description
    • 11.8.5 Hisun Pharma Related Developments
  • 11.9 Torrent Pharmaceuticals
    • 11.9.1 Torrent Pharmaceuticals Corporation Information
    • 11.9.2 Torrent Pharmaceuticals Overview
    • 11.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Description
    • 11.9.5 Torrent Pharmaceuticals Related Developments
  • 11.1 Celltrion
    • 11.1.1 Celltrion Corporation Information
    • 11.1.2 Celltrion Overview
    • 11.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Description
    • 11.1.5 Celltrion Related Developments

12 Value Chain and Sales Channels Analysis

  • 12.1 Biosimilar Monoclonal Antibodies Value Chain Analysis
  • 12.2 Biosimilar Monoclonal Antibodies Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Biosimilar Monoclonal Antibodies Production Mode & Process
  • 12.4 Biosimilar Monoclonal Antibodies Sales and Marketing
    • 12.4.1 Biosimilar Monoclonal Antibodies Sales Channels
    • 12.4.2 Biosimilar Monoclonal Antibodies Distributors
  • 12.5 Biosimilar Monoclonal Antibodies Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 Biosimilar Monoclonal Antibodies Industry Trends
  • 13.2 Biosimilar Monoclonal Antibodies Market Drivers
  • 13.3 Biosimilar Monoclonal Antibodies Market Challenges
  • 13.4 Biosimilar Monoclonal Antibodies Market Restraints

14 Key Findings in The Global Biosimilar Monoclonal Antibodies Study

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Author Details

    Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
    The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%.

    Market Analysis and Insights: Global Biosimilar Monoclonal Antibodies Market
    The global Biosimilar Monoclonal Antibodies market is valued at US$ 4574.3 million in 2019. The market size will reach US$ 25770 million by the end of 2026, growing at a CAGR of 27.7% during 2021-2026.

    Global Biosimilar Monoclonal Antibodies Scope and Market Size
    Biosimilar Monoclonal Antibodies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilar Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

    Segment by Type
    Infliximab
    Rituximab
    Trastuzumab
    Adalimumab
    Other

    Segment by Application
    Oncology
    Autoimmune Disease
    Other

    By Company
    Celltrion
    Pfizer (Hospira)
    3SBIO
    Novartis (Sandoz)
    Dr Reddy’s
    Celgen Biopharma
    Cadila Healthcare
    Hisun Pharma
    Torrent Pharmaceuticals

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia

    Buy now